Business context and reporting period
Incyte Corporation is a biopharmaceutical company with commercial products JAKAFI in the United States and ICLUSIG in Europe and other selected markets, alongside a partnered and internally developed pipeline. This Form 10-Q covers the quarter and nine months ended September 30, 2019; income and cash-flow comparisons are against the corresponding 2018 periods.
Financial results and liquidity
Amounts below are in USD millions, except per-share data and percentages.
| Metric | Q3 2019 | Q3 2018 | Nine months 2019 | Nine months 2018 |
|---|---|---|---|---|
| Total revenue | $551.6 | $449.7 | $1,579.4 | $1,353.5 |
| Operating income | $134.3 | $31.1 | $307.0 | $47.2 |
| Net income | $128.3 | $29.2 | $335.9 | $40.4 |
| Diluted EPS | $0.59 | $0.14 | $1.55 | $0.19 |
| Operating margin | 24.4% | 6.9% | 19.4% | 3.5% |
- Q3 revenue increased 22.7%; nine-month revenue increased 16.7%. JAKAFI product revenue was $433.4 million for Q3 and $1,218.5 million for the nine months. ICLUSIG revenue was $20.6 million and $65.6 million, respectively.
- Product royalties rose to $80.1 million for Q3 from $61.9 million, and to $217.7 million for the nine months from $165.6 million. OLUMIANT royalties increased to $21.6 million for Q3 and $56.8 million year to date.
- Milestone and contract revenue was $17.5 million for Q3 and $77.5 million for the nine months, down from $20.0 million and $120.0 million. 2019 year-to-date amounts included $40.0 million from Innovent, a $20.0 million Innovent milestone and $17.5 million from Zai Lab; 2018 included significant Lilly milestones.
- R&D expense declined to $281.3 million in Q3 and $841.2 million year to date, from $292.5 million and $893.7 million. Management attributed the year-to-date decline mainly to prior-year collaboration expenses and ending Incyte’s baricitinib co-funding. SG&A increased to $102.6 million in Q3 and $332.5 million year to date, partly reflecting higher personnel costs.
- Net cash provided by operations was $579.0 million for the nine months, versus $252.4 million. Investing used $57.4 million and financing provided $16.4 million. Cash, cash equivalents and marketable securities totaled approximately $2.0 billion at September 30; cash and cash equivalents alone were $1.70 billion.
- Total assets were $3.21 billion and stockholders’ equity was $2.42 billion. Current assets of $2.32 billion exceeded current liabilities of $461.7 million. Convertible notes had a carrying amount of $18.1 million, mature in 2020 and had a disclosed fair value of $28.4 million. The company also reported $282.0 million of acquisition-related contingent consideration and $56.2 million of lease liabilities.
Material changes, outlook and risks
- Profitability improved substantially versus 2018, with higher product and royalty revenue and lower R&D expense. The 2019 comparison also reflects investment gains: nine-month unrealized gains on long-term investments were $18.7 million, versus losses of $21.9 million in 2018. The nine-month fair-value charge for acquisition-related contingent consideration was $16.6 million.
- Management stated that operating cash flow and cash, cash equivalents and marketable securities should be adequate for capital needs for the foreseeable future. No specific revenue or earnings guidance was provided in the supplied filing text.
- Pipeline updates included the October 2019 announcement that the Novartis-sponsored REACH2 trial of ruxolitinib in steroid-refractory acute GVHD met its primary endpoint; REACH3 was recommended to continue without modification, with results expected in 2020. Novartis expected to submit a capmatinib NDA in Q4 2019. These are forward-looking or partner-dependent developments, not reported results for the quarter.
- Key exposures include reliance on JAKAFI, pricing and reimbursement pressure, competition (including potential generic competition), clinical-trial and regulatory uncertainty, dependence on collaborators and third-party manufacturers, and concentration among product customers. Four JAKAFI customers accounted for 38% of accounts receivable at quarter-end.
- The Department of Justice had issued a civil investigative demand concerning speaker programs and patient assistance programs. Incyte said it was cooperating; the outcome and any potential loss could not be estimated, and no reserve was recorded.
- In October 2019, Incyte agreed to purchase property for $50.0 million to expand its headquarters, subject to customary closing conditions. Separately, the 2020 convertible notes became convertible on October 1, 2019; management said it intended to settle conversions in shares.
Most important facts for investors to verify
- Whether JAKAFI growth and higher partner royalties continue, and how much sales are affected by pricing, rebates, reimbursement and customer purchasing patterns.
- How much reported earnings depend on milestone timing, investment fair-value changes and the remeasurement of contingent consideration.
- Progress, results and regulatory timing for key pipeline programs, especially REACH3, pemigatinib, itacitinib and capmatinib, including partner execution.
- Developments in the DOJ inquiry and any subsequent estimate, reserve or disclosure concerning possible loss.
- Settlement of convertible notes, completion and funding of planned facility projects, and changes in liquidity or contractual obligations.